Hydatidiform Mole Coexisting with Healthy and Alive Fetus at Birth: Case Report in Mexico

Juan Carlos Marin Mireles1*, Carla Eugenia Arenas Alvarez1, Adolfo Leyva Lopez1, Aldo Guadalupe Bucio Aguilar1, Pascal Patric Giuliano Friedlin Villalobos2 and Daniel Ponce de León Gonzalez1

1Gynaecology Department, General Hospital “Dr. Miguel Silva”, Morelia, Michoacan, Mexico.
2Gynaecology Department, Hospital “GINEQUITO”, Monterrey, Nuevo Leon, Mexico.

Authors’ contributions
This work was carried out in collaboration among all authors. Author JCMM collected the case data and was involved in writing the manuscript. Authors CEAA and ALL were involved in writing and editing the manuscript. Authors AGBA, PPGFV and DPLG wrote the discussion and participated in literature searches. All authors read and approved the final manuscript.

Article Information
DOI: 10.9734/AJMAH/2021/v19i430319
Editor(s):
(1) Dr. Ashish Anand, G V Montgomery Veteran Affairs Medical Center, USA.
Reviewers:
(1) Temesgen Tilahun, Wollega University, Ethiopia.
(2) Olga Plisko, Riga Stradins University, Latvia.
Complete Peer review History: http://www.sdiarticle4.com/review-history/68418

Received 01 March 2021
Accepted 07 May 2021
Published 10 May 2021

ABSTRACT

Aims: To describe a case of hydatidiform mole coexisting with healthy and alive fetus at birth in Mexico.

Presentation of Case: A 35 years old pregnant patient at 18+5 weeks of gestational age and a viable fetus by ultrasound, with atypical pneumonia, plus scant bilateral pleural effusion and partial mole implants on admission to hospital. At week 39 of gestation, the pregnancy was interrupted abdominally; a gestation product was obtained, alive, female, and without malformations. The patient did not present complications. The histopathological report of the placenta was compatible with a partial mole.

Discussion: Gestational trophoblastic disease includes partial hydatidiform mole, its occurrence in coexistence with alive and healthy fetus at birth is 0.005-0.01% respect to the total number of pregnancies. The viability of the term of pregnancy will depend on maternal comorbidities, fetaisss

*Corresponding author: E-mail: jcarlosmarinm@hotmail.com;
Mireles et al.; AJMAH, 19(4): 30-37, 2021; Article no.AJMAH.68418

well-being and accessible medical surveillance. The ultrasound is the main diagnostic tool. Clinical monitoring is of vital importance after the end of pregnancy, mainly in mother, due to the risk of developing metastatic disease and recurrence of molar pregnancy.

Conclusion: The case report described is relevant, due to its infrequency. In addition, the imaging findings, emphasizes the importance of a complete and adequate evaluation of the placenta and the fetus, in viable gestation conditions in coexistence with partial mole.

Keywords: Gestational trophoblastic disease; maternal health; perinatal health; placental abnormalities.

1. INTRODUCTION

In gestational trophoblastic disease, one of the less common entities is the coexistence of a partial hydatidiform mole with a healthy, alive fetus at birth [1]. This condition occurs between 0.005-0.01% respect to the total number of pregnancies [2,3]. It usually happens sporadically, having a multifactorial etiology [4].

The serious risks and complications that can occur during pregnancy, before and after delivery [5] require a timely differential diagnosis, providing the basis to proper management and follow-up. The objective of the present work is to describe a case of hydatidiform mole that coexists with alive and healthy fetus at birth in Mexico.

2. PRESENTATION OF CASE

A 35-years old pregnant patient. Pregnancy: four. Childbirth: three. With unknown date of last menstruation, without prenatal control, intake of folic acid, ferrous fumarate or immunizations, who initially attended General Hospital "La Piedad" in La Piedad de Cavada, Michoacan, Mexico on May 18, 2018. She had an intense headache of frontal location with eight days of evolution, unquantified febrile picture, dyspnea when performing minimal physical effort; and denying abdominal pain or transvaginal leakage. She was hospitalized for four days due to a probable infectious focus of a pulmonary location. A chest x-ray confirmed an infectious pulmonary process, which was treated; and absence of metastasis. In the obstetric ultrasound, multiple circumscribed, round intraplacental lesions, typical of partial mole, were observed; without apparent fetal alterations and a gestational age of 18+5 weeks (Fig. 1). Estimated date of delivery: October 16, 2018. Fetal karyotyping was not performed due to lack of resources in the hospital.

The results of hematic biometry, lipid profile, thyroid function, and general urine were found in normal ranges. The liver and blood chemistry tests are shown in Table 1, in which minimal alterations are observed, probably due to the physiology of pregnancy. Negative to hepatitis B and C antibodies, as well as HIV. Two quantifications of β-HCG were carried out, registering values of 18,261 and 15,801 mIU/ml. The blood group of the patient was A Rh (+) and her husband O Rh (−). Blood pressure in all consultations was below 140/90 mmHg, ruling out preeclampsia. On June 1, 2018, she was discharged due to an improvement in her respiratory condition. The patient was informed of possible risks of abortion, congenital malformations and metastasis, however, by her decision and relatives, she continued with the pregnancy. She was followed up, indicating a monthly prenatal checkup, including ultrasound, hematic biometry, liver and thyroid function tests.

The termination of the pregnancy was carried out on October 10, 2018, via caesarian section, with a gestational age of 39 weeks, and the patient's hemodynamic stability. By ultrasonographic tracing, the fetus presented right back longitudinal cephalic position, a fetal heart rate of 145 beats/minute. An anterior corporal placenta was observed, with cystic areas and lacunar areas due to a partial mole (Fig. 2) in addition, a probable subchorionic hematoma measuring 6x7
cm. Alive newborn was obtained, female, 3,130 g, height 52 cm, cephalic perimeter 34 cm, thoracic of 33 cm, abdominal 31 cm, foot 8 cm, umbilical cord with three vessels, APGAR 8-9. The amniotic fluid was normal and the placenta was completely extracted, its histopathological report concluded a partial mole (Fig. 3).

Fig. 1. Ultrasound image performed on May 22, 2018, demonstrating alive and healthy fetus with 18+5 weeks of gestation, as well as parts of the molar tissue (a); color doppler performed on May 28, 2018 showing partial mole (b)
### Table 1. Blood chemistry and liver function tests during hospitalization

<table>
<thead>
<tr>
<th>Clinical study</th>
<th>Date and time of sampling</th>
<th>Date and time of sampling</th>
<th>Date and time of sampling</th>
<th>Date and time of sampling</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>01:52 a.m.</td>
<td>07:55 a.m.</td>
<td>05:54 p.m.</td>
<td>07:46 a.m.</td>
</tr>
</tbody>
</table>

#### Blood chemistry

<table>
<thead>
<tr>
<th>Test</th>
<th>66</th>
<th>60</th>
<th>73</th>
<th>69</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose (mg/dL)</td>
<td>66</td>
<td>60</td>
<td>73</td>
<td>69</td>
</tr>
<tr>
<td>Urea (mg/dL)</td>
<td>10.1</td>
<td>11.6</td>
<td>8.7</td>
<td>8.5</td>
</tr>
<tr>
<td>Blood urea nitrogen-BUN (mg/dL)</td>
<td>4.7</td>
<td>5.4</td>
<td>4.1</td>
<td>4.0</td>
</tr>
<tr>
<td>Glomerular filtration rate (mL/min)</td>
<td>133.22</td>
<td>137.68</td>
<td>140.15</td>
<td>137.68</td>
</tr>
<tr>
<td>Serum creatinine (mg/dL)</td>
<td>0.42</td>
<td>0.38</td>
<td>0.36</td>
<td>0.38</td>
</tr>
<tr>
<td>Uric acid (mg/dL)</td>
<td>2.31</td>
<td>1.20</td>
<td>1.20</td>
<td>1.50</td>
</tr>
<tr>
<td>Cholesterol (mg/dL)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>150.5</td>
</tr>
<tr>
<td>Triglycerides (mg/dL)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>466.20</td>
</tr>
<tr>
<td>Lactic dehydrogenase (U/L)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>899</td>
</tr>
</tbody>
</table>

#### Liver function tests

<table>
<thead>
<tr>
<th>Test</th>
<th>274</th>
<th>177</th>
<th>-</th>
<th>181</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspartate aminotransferase (U/L)</td>
<td>137</td>
<td>108</td>
<td>-</td>
<td>119</td>
</tr>
<tr>
<td>Alanine aminotransferase (U/L)</td>
<td>125.3</td>
<td>121.0</td>
<td>-</td>
<td>200.0</td>
</tr>
<tr>
<td>Alkaline phosphatase (U/L)</td>
<td>169.0</td>
<td>242.4</td>
<td>-</td>
<td>97.6</td>
</tr>
<tr>
<td>C-reactive protein (mg/L)</td>
<td>4.2</td>
<td>4.4</td>
<td>-</td>
<td>5.9</td>
</tr>
<tr>
<td>Total proteins (g/dL)</td>
<td>2.1</td>
<td>2.0</td>
<td>-</td>
<td>2.8</td>
</tr>
<tr>
<td>Albumin (g/dL)</td>
<td>2.1</td>
<td>2.4</td>
<td>-</td>
<td>3.1</td>
</tr>
<tr>
<td>Globulins (g/dL)</td>
<td>1.0</td>
<td>0.8</td>
<td>-</td>
<td>0.9</td>
</tr>
<tr>
<td>A/G ratio</td>
<td>1.18</td>
<td>1.04</td>
<td>-</td>
<td>1.40</td>
</tr>
<tr>
<td>Total bilirubin (mg/dL)</td>
<td>0.88</td>
<td>0.76</td>
<td>1.10</td>
<td>0.30</td>
</tr>
<tr>
<td>Direct bilirubin (mg/dL)</td>
<td>0.30</td>
<td>0.28</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Indirect bilirubin (mg/dL)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
Fig. 2. Ultrasound images performed on October 10, 2018, showing a healthy and alive fetus with 39 weeks of gestation, as well as parts of the molar tissue (a) color doppler showing partial mole (b)
3. DISCUSSION

Gestational trophoblastic disease includes a large number of tumors that are interrelated, and with different propensities for local invasion and metastasis. Presenting as complete and partial hydatidiform mole, invasive mole, choriocarcinoma, placental site trophoblastic tumor, and epithelioid trophoblastic tumor [5,6].

The incidence of gestational trophoblastic disease varies according to the geographical area [7], in Mexico it is estimated to be 2.4 per 1,000 pregnancies; in invasive mole 1 in 40 molar pregnancies, and in 1 in 150,000 normal pregnancies [8]. In the case of partial hydatidiform mole, its occurrence in coexistence with alive and healthy fetus at birth worldwide is between 0.005-0.01% with respect to the total number of pregnancies [2,3].

Risk factors related to gestational trophoblastic disease are: under 20 years or older than 35 years, enlarged uterus, bilateral luteal cysts, blood types (A and AB), recurrent pregnancy loss, hyperthyroidism, molar pregnancy prior and use of contraceptives methods [9,10]. The only factor that matches this case report is blood group type.

Viability at term of pregnancy will depend on maternal comorbidities, fetal well-being and accessible medical surveillance [7] coinciding with the present case report, since the patient and the fetus did not develop complications. Carrying out clinical studies (hematimetry, blood chemistry, liver and thyroid function tests, β-HCG) during pregnancy are of vital importance [11,12].

In addition to the follow-up of clinical studies, ultrasound is the main diagnostic tool to early and adequate identification of possible gestational trophoblastic disease [12]. Clinical follow-up has a vital importance after the end of pregnancy, mainly in mother, due to the risk of developing metastatic disease and recurrence of molar pregnancy. Therefore, the histopathological study of the placenta is a required [13].

4. CONCLUSION

The case report described is relevant, due to its infrequency, in addition the imaging findings, emphasizes the importance of a complete and adequate evaluation of the placenta and the fetus in viable gestation conditions in coexistence with partial mole. The viability of the term of
pregnancy will depend on maternal comorbidities, fetal well-being and accessible medical surveillance. Clinical monitoring has vital importance after the end of pregnancy, mainly in mother, due to the risk of developing metastatic disease and recurrence of molar pregnancy. Finally, it is recommended to continue a research related to the subject, in order to provide alternatives that improve maternal and perinatal health.

CONSENT

All authors declare that written informed consent was obtained from the patient for publication of this case report and accompanying images.

ETHICAL APPROVAL

The research work was examined and approved by the hospital research and ethics committee.

ACKNOWLEDGEMENTS

The authors appreciate the patient that participated in this research.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES


© 2021 Mireles et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
http://www.sdiarticle4.com/review-history/68418